IFNA1 and neoplasm: However, persistent IFN signaling leads to T cell exhaustion and unfavorable ICB responses (47, 88–90), and more studies would be needed to investigate which patient subsets (early or advanced tumor, with or without combination with ICB) may benefit from this strategy.